Premium
Inhibition of Thromboplastic Activity by Trasylol®
Author(s) -
Amris C. J.,
Hilden M.
Publication year - 1967
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1967.tb01592.x
Subject(s) - thromboplastin , in vivo , chemistry , in vitro , pharmacology , coagulation , thrombin , medicine , biochemistry , biology , platelet , microbiology and biotechnology
In vitro experiments with the thromboplastin activation test (TAT) indicate that Trasylol primarily is an inhibitor of the contact phase of intrinsic clotting. However, also later stages seem to be inhibited to a certain extent. The activating effect of serum and brain thromboplastin on the thromboplastin activation was prevented or reduced by Trasylol but the activating effect of minimal amounts of thrombin was only slightly reduced. The possible significance of the findings in vivo are briefly discussed.